Patents by Inventor Olivier Michielin

Olivier Michielin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multispecific antigens binding fragments and multispecific antibodies
    Patent number: 11945879
    Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 2, 2024
    Assignees: Jean Kadouche, Centre National de la Recherche Scientifique, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, University of Lausanne
    Inventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
  • Kinase mutants and uses thereof
    Patent number: 11738049
    Abstract: The present invention relates to methods of designing kinase mutants for reprogramming the sensitivity of a target kinase to some specific inhibitors, methods of reprogramming the sensitivity of a target kinase to some specific inhibitors, wherein those kinase inhibitors have little or no affinity for the wild-type target kinase, vectors or cells expressing said mutated kinases, composition and uses thereof for the prevention and/or treatment of a disease or disorder, in particular cancer.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: August 29, 2023
    Assignees: SIB Swiss Institute of Bioinformatics, CHUV—Centre Hospitalier Universitaire Vaudois, Université de Lausanne, Ludwig Institute for Cancer Research Ltd
    Inventors: Olivier Michielin, Vincent Zoete, George Coukos, Melita Irving, Nahzli Dilek, Patrick Reichenbach, Kelly Ascencao
  • A2/NY-ESO-1 SPECIFIC T CELL RECEPTORS AND USES THEREOF
    Publication number: 20220152109
    Abstract: The application provides genetically modified cell receptors (TCRs) specific for an epitope from cancer antigen NY-ESO-1. Also provided are related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells, including but not limited to genetically engineered cells, and pharmaceutical compositions. The application further provides the use of such modified T cell receptors (TCRs) and related compositions for cancer immunotherapy (e.g., adoptive cell therapy).
    Type: Application
    Filed: March 17, 2020
    Publication date: May 19, 2022
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: George COUKOS, Melita IRVING, Vincent ZOETE, Olivier MICHIELIN
  • Multispecific Antibodies
    Publication number: 20210040235
    Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CHI and CL domains, said mutations preventing heavy chain/light chain mispairing.
    Type: Application
    Filed: August 18, 2020
    Publication date: February 11, 2021
    Inventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
  • Multispecific Antibodies
    Publication number: 20200385490
    Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CHI and CL domains, said mutations preventing heavy chain/light chain mispairing.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 10, 2020
    Inventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
  • Multispecific antigen binding fragments and multispecific antibodies derived therefrom comprising mutant CH1 and CL-kappa domains
    Patent number: 10815310
    Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: October 27, 2020
    Assignees: Centre National de la Recherche Scientifique, Azienda socio sanitaria territoriale Papa Giovanni XXIII, Universite de Lausanne
    Inventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
  • KINASE MUTANTS AND USES THEREOF
    Publication number: 20200101110
    Abstract: The present invention relates to methods of designing kinase mutants for reprogramming the sensitivity of a target kinase to some specific inhibitors, methods of reprogramming the sensitivity of a target kinase to some specific inhibitors, wherein those kinase inhibitors have little or no affinity for the wild-type target kinase, vectors or cells expressing said mutated kinases, composition and uses thereof for the prevention and/or treatment of a disease or disorder, in particular cancer.
    Type: Application
    Filed: May 24, 2018
    Publication date: April 2, 2020
    Inventors: Olivier Michielin, Vincent Zoete, George Coukos, Melita Irving, Nahzli Dilek, Patrick Reichenbach, Kelly Ascencao
  • MULTISPECIFIC ANTIGENS BINDING FRAGMENTS AND MULTISPECIFIC ANTIBODIES DERIVED THEREFROM COMPRISING MUTANT CH1 AND CL-KAPPA DOMAINS
    Publication number: 20180022829
    Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.
    Type: Application
    Filed: March 20, 2017
    Publication date: January 25, 2018
    Inventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
  • Multispecific antigens binding fragments and multispecific antibodies derived therefrom comprising mutant CH1 and CL-? domains
    Patent number: 9631031
    Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy/light chain mispairing.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: April 25, 2017
    Assignees: Centre National de la Recherche Scientifique, Azienda Ospedaliera Papa Giovanni XXIII, Universite de Lausanne
    Inventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
  • MULTISPECIFIC MUTATED ANTIBODY FAB FRAGMENTS
    Publication number: 20140242076
    Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy/light chain mispairing.
    Type: Application
    Filed: July 6, 2012
    Publication date: August 28, 2014
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE LAUSANNE, AZIENDA OSPEDALIERA PARA GIOVANNI XXIII
    Inventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay